CVS, the largest U.S. pharmacy chain, overbilled consumers who used insurance to pay for some generic drugs and wrongfully hid the fact that the medicines’ cash price was cheaper, Megan Schultz said in her Aug. 7 lawsuit. Schultz said in one case she paid $166 for a generic drug that would have cost only $92 if she’d known to pay cash.
CVS “remained silent and took her money” because the chain was in cahoots with the pharmacy benefit managers who got the extra co-pay money, she said in the suit. The “clawbacks’’ of Schultz’s generic-drug co-pays were made under CVS’s agreements with PBMs such as Express Scripts Holding Co. and CVS Caremark, according to the suit filed Monday in federal court in Rhode Island. CVS is based in that state.
“CVS, motivated by profit, deliberately entered into these contracts, dedicating itself to the secret scheme that kept customers in the dark about the true price’’ of drugs they purchased, Schultz’s lawyers said in the suit, which is seeking class-action status.
CVS officials rejected Schultz’s claims and said the co-pays are determined by the benefit managers. “The allegations against us made in this proposed class action suit are built on a false premise and are completely without merit,’’ CVS spokesman Michael DeAngelis said Tuesday in an email.
The CVS lawsuit follows at least 16 other suits around the U.S. targeting drugstore chains’ co-pay clawbacks. The practice occurs when patients pay co-payments set by a benefit manager that exceed the actual cash cost of the drug. The benefit managers pocket the difference.
Suits over the practice have been filed against UnitedHealth Group Inc., which runs the benefit manager OptumRx; Cigna Corp., which contracts with OptumRx; and Humana Inc. They allege that the benefit managers defrauded consumers and violated federal laws.